Comparative bioavailability of two cefdinir suspension formulations in Middle Eastern healthy volunteers after single oral administration

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 3, 2008, Pages 149-153

  Zaid, Abdel Naser ^a   Alhaique, Franco ^b   Kort, Jamal ^c   Sweileh, Waleed ^a  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Pharmacare Chemical and Cosmetics   (Palestine)

Author keywords

Adcef ; Antibacterials; CAS 91832 40 5; Cefdinir, bioequivalence, Middle Eastern volunteers

Indexed keywords

ADCEF; CEFDINIR; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL MODEL;

EID: 41849100401     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296485     Document Type: Article

References (11)

1. Inamoto Y, Chiba T, Kamimura T, Takaya T. FK482, a new orally active cephalosporin synthesis and biological properties. J Antibiot (Tokyo). 1988;41:828-830.
2. Sakane K, Inamoto Y, Takaya T. A new oral cephem, cefdinir: its structure-activity relationships and biological profile. Jpn J Antibiot. 1992;45:909-925.
3. Montvale NJ, Thomson PDR. Physicians Desk Reference, 57th ed. [M]. Oradell (New Jersey): Medical Economics; 2003. p 489.
4. Arguedas A, Dagan R, Leibovitz E, Hoberman A, Pichichero M, Paris M. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J. 2006;25:211-218.
5. Hardley JA. The efficacy of cefdinir in acute bacterial rhinosinusitis. Expert Opin Pharmacol. 2006;7:1075-1083.
6. Holas C, Chiu YL, Notario G., Kapral D. A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clin Ther. 2005;27:1950-1960.
7. Shimada K, Oka S. Effect of food on bioavailability of cefdinir. Chemotherapy (Tokyo). 1989;37 (Suppl 2):246-256.
8. Shimada K, Shishido A, Tsunoo M. Phase 1 study of cefdinir. Chemotherapy (Tokyo). 1989;37 (Suppl 2):208-245.
9. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992.
10. EMEA guidance. Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). London; 26 July 2001.
11. FDA guidance. Guidance for industry: Statistical approaches to establishing bioequivalence. Rockville, MD; 31 January 2001.